OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio logical drug products in various injectable formats. It also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologicsBusiness Overview: OSSPL is a subsidiary of Strides Pharma Ltd. The...
OneSource Specialty Pharma has issued an addendum to its upcoming annual general meeting notice, incorporating additional disclosures and audit committee reviews regarding proposed related party transactions to ensure full transparency for shareholders ahead of the meeting.
The provided document is an "Intimation of Investor Presentation," which announces that an investor meeting was held and the investor presentation has been uploaded to the company's website. As the actual content of the investor presentation (details on business performance, growth drivers, financials, etc.) is not included in this document,...
Onesource Specialty Pharma Limited has informed the Exchange about Copy of Newspaper Publication confirming dispatch of Notice of the 19th Annual GeneralMeeting (AGM) and Remote e-voting
OneSource Specialty Pharma's FY26 BRSR shows improved environmental performance with major NOx/SOx emission cuts and enhanced energy/water efficiency from new systems. Accounts payable days doubled to 163.75, while related party sales share dropped to 29.12%. CSR spend reached ₹2.15 Cr.
Onesource Specialty Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 23, 2026
